title: Management of low-grade gliomas: a review of patient-perceived quality of life and neurocognitive outcome.
abstract: Low-grade glioma (LGG) comprises nearly 20% of all central nervous system glial tumors, with approximately 2000-3000 patients diagnosed annually in the United States. Because of their infiltrative ability and aggressive nature, the average 10-year survival is 30% when <90% of the tumor is resected. Since the 1970s, prognosis for LGGs has improved significantly. This improvement is primarily attributable to earlier diagnoses via magnetic resonance imaging scanning, increased awareness of the more favorable oligo component, technical advances in intraoperative neurosurgery, and stratification for young age. Using a number of prognostic factors, LGGs have been classified into low-risk and high-risk subgroups. Optimal therapy for patients with low-risk, supratentorial grade II glioma remains a highly controversial issue in the neuro-oncology community. The concerns regarding the toxicity of therapy often outweigh the benefits of delaying tumor progression. The recommendation for observation is made without full prospective understanding of the impact of radiologic tumor progression on the quality of life (QOL), neurocognitive function (NCF), seizure control, and functional status of these patients. We present a review of the current knowledge of the management of LGG with emphasis upon patient-reported outcomes of QOL, NCF, and seizure control. We also discuss current clinical trials with proposals to evaluate QOL, NCF, and seizure control in patients undergoing observation alone after newly diagnosed low-risk LGG or treatment options for those patients in the high-risk group.
authors.affiliation: Norton Neuroscience Institute and Norton Cancer Institute, Norton Healthcare, Louisville, Kentucky, USA. Electronic address: LBES@earthlink.net.
authors.forename: Lisa B E
authors.initials: LB
authors.lastname: Shields
authors.affiliation: Norton Neuroscience Institute and Norton Cancer Institute, Norton Healthcare, Louisville, Kentucky, USA.
authors.forename: Ali K
authors.initials: AK
authors.lastname: Choucair
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001931:Brain Mapping; D001932:Brain Neoplasms / Q000523:psychology / Q000532:radiotherapy / Q000601:surgery* / Q000628:therapy*; D003071:Cognition / Q000502:physiology*; D003131:Combined Modality Therapy; D005910:Glioma / Q000523:psychology / Q000532:radiotherapy / Q000601:surgery* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008279:Magnetic Resonance Imaging; D009483:Neuropsychological Tests; D019635:Neurosurgical Procedures; D011379:Prognosis; D011788:Quality of Life; D012640:Seizures / Q000453:epidemiology / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: Brain tumor; Cognitive function; Low-grade glioma; Quality of life; Seizures